UCB SA (UCBB.XC)

Compare

180.23

0.00

(0.00%)

At close: February 27 at 3:20:41 PM GMT

UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

UCB SA (UCBJF) reports a robust 17% revenue increase, driven by key growth drivers and strategic market expansions, despite facing pricing pressures and increased expenses.

GuruFocus.com 3 hours ago

UCBJY
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB Full-Year Report 2024, Brussels (Belgium) – regulated information

PR Newswire 4 days ago

UCBJF

UCBJY
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx) is now available. These are in addition to the currently available 1 mL device administration options, each containing 160 mg of BIMZELX.

PR Newswire last month

UCBJF

UCBJY
USNA or UCBJY: Which Is the Better Value Stock Right Now?

USNA vs. UCBJY: Which Stock Is the Better Value Option?

Zacks 2 months ago

UCBJY

USNA
Roche’s Parkinson’s Drug Candidate Misses Key Goal in Mid-Stage Study

An experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.

The Wall Street Journal 2 months ago

RHHBF

RHHBY

RHHVF
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

UCB, a global biopharmaceutical company, today announced data being presented at the American Epilepsy Society (AES) Annual Meeting, taking place December 6–10 in Los Angeles, California, that focus on the impact and burden of epilepsy on people living with epilepsy and their caregivers.

PR Newswire 2 months ago

UCBJF

UCBJY
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

UCB today announced it will present 32 abstracts from its expansive epilepsies research program at the American Epilepsy Society (AES) Annual Meeting, December 6-10, 2024 (Los Angeles, California). The data will include clinical and real-world data, plus medical research from across UCB's pipeline programs.

PR Newswire 3 months ago

UCBJF

UCBJY
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus erythematosus. The drug candidate demonstrated significant clinical improvement in disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE). Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The

Benzinga 3 months ago

BIIB

UCBJY
UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).1 BIMZELX is the first and only approved medicine designed to selectively inhibit interleukin 17F (IL-17F) in addition to interleukin 17A (IL-17A).1

PR Newswire 3 months ago

UCBJF

UCBJY
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activityA greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care aloneSystemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ sy

GlobeNewswire 3 months ago

UCBJF

UCBJY

BIIB
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

UCB, a global biopharmaceutical company, today announced the presentation of new two-year data confirming a sustained clinical response for the IL-17A and IL-17F inhibitor BIMZELX® (bimekizumab-bkzx), in adults with active psoriatic arthritis (PsA) and those with active non-radiographic axial spondyloarthritis with objective signs of inflammation (nr-axSpA) and active ankylosing spondylitis (AS). These results are the latest from the Phase 3 studies BE OPTIMAL (PsA), BE COMPLETE (PsA), and their

PR Newswire 3 months ago

UCBJF

UCBJY
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it will be presenting results from across its portfolio in generalized myasthenia gravis (gMG) at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session taking place October 15—18, 2024 at the Savannah Convention Center in Savannah, Georgia, U.S.

PR Newswire 4 months ago

UCBJF

UCBJY
UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with SKYRIZI® (risankizumab), an IL-23 inhibitor, in the treatment of adults with active psoriatic arthritis (PsA). BE BOLD is the first head-to-head study in PsA evaluating the superiority of an IL-17A and IL-17F inhibitor to an IL-23 inhibitor.

PR Newswire 4 months ago

UCBJF

UCBJY
UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB, a global biopharmaceutical company, today announced the first presentation of two-year data from the Phase 3 studies, BE HEARD I and BE HEARD II, and their open-label extension, evaluating the efficacy and safety of BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, in adults with moderate-to-severe hidradenitis suppurativa (HS).1 These new data are presented today as a late-breaking platform presentation at the 33rd European Academy of Dermatology and Venereology (E

PR Newswire 5 months ago

UCBJF

UCBJY
UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

UCB, a global biopharmaceutical company, today announced the presentation of new four-year data in patients with moderate-to-severe plaque psoriasis treated with BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor. These post-hoc analyses include maintenance of response through four years in BIMZELX patients who achieved near-complete or complete skin clearance after one year, and the clinical response up to four years in patients switching to BIMZELX following an inadequat

PR Newswire 5 months ago

UCBJF

UCBJY
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) released topline results from the Phase 3 PHOENYCS GO study of dapirolizumab pegol for moderate-to-severe systemic lupus erythematosus (SLE). SLE is a chronic autoimmune disease that can affect many organs in the body. It occurs when the body’s immune system attacks healthy tissue, causing inflammation and sometimes permanent tissue damage. SLE can present itself in several ways, including rash, arthritis, anemia, thrombocytop

Benzinga 5 months ago

BIIB

UCBJY
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.UCB and Biogen are advancing dapirolizumab pegol with the objective to address the substantial unmet medical need for people living with SLE, where there are limited treatment options.SLE is a chronic, debilitating autoimmune disease that affects multiple or

GlobeNewswire 5 months ago

BIIB

UCBJF

UCBJY
UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis (AS).1 BIMZELX is the first approved treatment for these three indications that is designed to selectively inhibit two key cytokine

PR Newswire 5 months ago

UCBJF

UCBJY
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB

Thursday, Johnson & Johnson (NYSE:JNJ) announced the submission of a Biologics License Application (BLA) to the FDA seeking the first approval of nipocalimab globally for generalized myasthenia gravis (gMG). gMG is an autoantibody-driven neuromuscular disease characterized by fluctuating muscle weakness. The update marks the first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce autoantibody levels. Also Read: Car

Benzinga 6 months ago

JNJ

ARGX

UCBJY
Belgium stocks higher at close of trade; BEL 20 up 0.33%

Investing.com – Belgium stocks were higher after the close on Thursday, as gains in the Healthcare, Telecoms and Basic Materials sectors led shares higher.

Investing.com 6 months ago

UCBJY

Performance Overview

Return	UCBB.XC	BEL 20
YTD	-2.32%	+5.77%
1-Year	+92.52%	+20.84%
3-Year	+88.16%	+12.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

UCB SA (UCBB.XC)

UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

USNA or UCBJY: Which Is the Better Value Stock Right Now?

Roche’s Parkinson’s Drug Candidate Misses Key Goal in Mid-Stage Study

UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB

Belgium stocks higher at close of trade; BEL 20 up 0.33%

Performance Overview